<DOC>
	<DOCNO>NCT00142454</DOCNO>
	<brief_summary>This study evaluate cancer vaccine melanoma patient resect melanoma high risk recurrence ( stag IIB-III ) . This single arm , open label , pilot/phase I study evaluate safety immunogenicity NY-ESO-1 protein vaccination Imiquimod adjuvant . Imiquimod FDA approve immune response modifier treatment HPV associate genital wart ( use different indication ) show attract mature dendritic cell area topical application . This utilized application inject protein vaccine site , prime boost anti-NY-ESO-1 immune response . 9 patient treat receive 4 vaccination cycle , 21 day apart . Each vaccination cycle consist topical application Imiquimod 250mg healthy skin extremity first five day cycle intradermal injection NY-ESO-1 protein 100mcg pretreated area day 3 . Immunization assess T-cell assay , NY-ESO-1 specific antibody titer , evaluation 3 small skin biopsy .</brief_summary>
	<brief_title>NY-ESO-1 Protein Vaccine With Imiquimod Melanoma ( Adjuvant Setting )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Histologically confirm , resect AJCC Stage IIB , IIC III malignant melanoma Fully recover surgery Age &gt; 18 year . ECOG performance status &lt; 2 Adequate organ marrow function . Ability understand willingness sign write informed consent document . Chemotherapy , immunotherapy ( include interferon ) , radiotherapy within 4 week prior first dose study agent . Prior treatment NYESO1 vaccine . Known HIV infection autoimmune disease ( RA , SLE ) . Patients vitiligo melanomaassociated hypopigmentation exclude . History allergic reaction attribute compound similar chemical biologic composition imiquimod agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception . Patients known history inflammatory skin disorder , imiquimod might exacerbate condition . Patients receive chronic corticosteroid immunosuppressive therapy . Lack availability immunological clinical followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Malignant melanoma</keyword>
	<keyword>Stages IIB-III</keyword>
</DOC>